Effect of protocolized weaning with early extubation to non-invasive ventilation vs invasive weaning on time to liberation from mechanical ventilation among patients with respiratory failure : the Breathe randomized trial by Perkins, Gavin D. et al.
Effect of ProtocolizedWeaningWith Early Extubation
to Noninvasive Ventilation vs InvasiveWeaning
on Time to Liberation FromMechanical Ventilation
Among PatientsWith Respiratory Failure
The Breathe Randomized Clinical Trial
Gavin D. Perkins, MD; DipeshMistry, PhD; Simon Gates, PhD; Fang Gao, MD; Catherine Snelson, MB; Nicholas Hart, PhD;
Luigi Camporota, PhD; James Varley, MB; Coralie Carle, MB; Elankumaran Paramasivam, MB; Beverley Hoddell;
Daniel F. McAuley, MD; Timothy S. Walsh, MD; Bronagh Blackwood, PhD; Louise Rose, PhD; Sarah E. Lamb, DPhil;
Stavros Petrou, PhD; Duncan Young, DM; Ranjit Lall, PhD; for the Breathe Collaborators
IMPORTANCE In adults in whomweaning from invasive mechanical ventilation is difficult,
noninvasive ventilationmay facilitate early liberation, but there is uncertainty about its
effectiveness in a general intensive care patient population.
OBJECTIVE To investigate among patients with difficulty weaning the effects of protocolized
weaning with early extubation to noninvasive ventilation on time to liberation from
ventilation compared with protocolized invasive weaning.
DESIGN, SETTING, AND PARTICIPANTS Randomized, allocation-concealed, open-label,
multicenter clinical trial enrolling patients betweenMarch 2013 and October 2016 from 41
intensive care units in the UK National Health Service. Follow-up continued until April 2017.
Adults who received invasive mechanical ventilation for more than 48 hours and in whom
a spontaneous breathing trial failed were enrolled.
INTERVENTIONS Patients were randomized to receive either protocolized weaning via early
extubation to noninvasive ventilation (n = 182) or protocolized standard weaning (continued
invasive ventilation until successful spontaneous breathing trial, followed by extubation)
(n = 182).
MAINOUTCOMES ANDMEASURES Primary outcomewas time from randomization to successful
liberation fromall forms ofmechanical ventilation among survivors,measured in days, with the
minimal clinically important difference defined as 1 day. Secondary outcomeswere duration of
invasive and total ventilation (days), reintubation or tracheostomy rates, and survival.
RESULTS Among 364 randomized patients (mean age, 63.1 [SD, 14.8] years; 50.5%male), 319
were evaluable for the primary effectiveness outcome (41 died before liberation, 2withdrew,
and 2were dischargedwith ongoing ventilation). Themedian time to liberationwas 4.3 days
in the noninvasive group vs 4.5 days in the invasive group (adjusted hazard ratio, 1.1; 95%CI,
0.89-1.40). Competing risk analysis accounting for deaths had a similar result (adjusted hazard
ratio, 1.1; 95%CI, 0.86-1.34). The noninvasive group received less invasive ventilation (median,
1 day vs 4 days; incidence rate ratio, 0.6; 95%CI, 0.47-0.87) and fewer total ventilator days
(median, 3 days vs 4 days; incidence rate ratio, 0.8; 95%CI, 0.62-1.0). Therewas no significant
difference in reintubation, tracheostomy rates, or survival. Adverse events occurred in 45
patients (24.7%) in the noninvasive group comparedwith 47 (25.8%) in the invasive group.
CONCLUSIONS AND RELEVANCE Among patients requiringmechanical ventilation in whom
a spontaneous breathing trial had failed, early extubation to noninvasive ventilation did not
shorten time to liberation from any ventilation.
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I nvasive mechanical ventilation is a lifesaving interven-tion.However, prolongedventilation is associatedwith in-creasedmorbidity andmortality.1,2 Optimal processes for
weaning from ventilation have been studied for many years
andhave led to evidence-based clinical practice guidelines to
facilitateearly liberationfrominvasivemechanicalventilation.3
These guidelines recommend using spontaneous breathing
trials,minimizingsedation,usingweaningprotocols, andearly
mobilization to promote liberation from ventilation.
Althoughmost invasively ventilated patients have anun-
complicated (simple) weaning pathway, about one-third re-
quiremore than 1 spontaneous breathing trial and are consid-
ereddifficult towean.1,4,5 Patientswithdifficultyweaning face
thephysical discomfort of ongoing tracheal intubation, are of-
ten unable to speak,6 and are at increased risk of ventilator-
associated pneumonia.7,8 Mobilization is often delayed be-
causeofconcurrent sedationandconcernsaboutunintentional
extubation.9,10 This group of patients consume a dispropor-
tionate amount of intensive care unit (ICU) resources.11
Noninvasivemechanical ventilation, which is being used
increasingly as an alternative to invasive ventilation,12,13may
have a role in supporting early liberation from invasive me-
chanical ventilation in patients who have difficulty weaning.
Although the use of noninvasive ventilation as an adjunct to
weaninghasbeen tested inprevious studies, thepatientpopu-
lations and interventions tested are not generalizable to con-
temporary clinical ventilation practice.14
In thismulticenter randomized clinical trial conducted in
the United Kingdom, it was hypothesized that weaning pro-
tocols that directed clinicians to extubate patients who were
difficult to wean to noninvasive ventilation, compared with
conventionalweaningprotocols for invasivemechanical ven-
tilation,would reduce the time to liberation fromventilation.
Methods
Trial Design
Weconductedthisrandomized,allocation-concealed,controlled,
open-label, multicenter trial in 41 general adult ICUs in the
UnitedKingdom.The trialprotocolwasdesignedbythe trial in-
vestigators (Supplement 1) andwas approvedbySouthCentral
CResearchEthicsCommittee (reference 12/SC/0515). Itwasen-
dorsedbytheUKIntensiveCareFoundation.Writtenconsentwas
obtainedfrompatients, theirnextofkin,oraphysicianwhowas
independent fromthetrialprior torandomization inaccordance
withnational laws.Thestudyincludedaninternalpilotspanning
the first 6 months of the trial, at which point progress was re-
viewedby the funder. The same trial protocolwas used for the
internal pilot as for themain study. Patients enrolled in the in-
ternal pilotwere included as part of themain trial.
Patients
Adult patients who had received invasive mechanical venti-
lation through an endotracheal tube continuously for more
than48hoursandwere ready tocommenceweaningwerecon-
sideredforenrollment.Exclusioncriteriawerepregnancy,pres-
enceof a tracheostomy, contraindications tononinvasiveven-
tilation, profoundneurological deficit, homeventilationprior
to admission, treatment limitations, need for further surgery
or sedation, or no noninvasive ventilator available. Readi-
ness toweanwas assessedby the treating clinicianbefore ran-
domizationaccording toprespecifiedcriteria.15Patients judged
readytostartweaningunderwentaspontaneousbreathing trial
(eAppendix in Supplement 2). Patients in whom the sponta-
neous breathing trial failed were defined as difficult to wean
andwere eligible for randomization. After obtaining consent,
eligiblepatientswererandomizedusingweb-basedsecureelec-
tronic randomization designed by the study statistician. The
minimizationmethodwas used to randomize patients in a 1:1
(noninvasive or invasive) allocation. The stratifying factors
used in the minimization algorithmwere center, presence or
absenceof chronicobstructivepulmonarydisease (COPD), and
postoperative/nonoperative reason for ICU admission, and
these ensured equal balance between treatment groups.
Chronic obstructive pulmonary diseasewas defined by a pre-
admissiondiagnosis ofCOPDrequiringpharmacological treat-
ment, evidence of a ratio of forced expiratory volume in the
first second to forced vital capacity of less than0.7 (FEV1/FVC
<0.7) and an FEV1 less than 80% of predicted, or presence of
respiratory symptoms. Patients admitted to the ICU after sur-
gery were defined as the postoperative group. Following the
spontaneousbreathing trial, pressure support ventilationwas
reestablishedusing theprevioussettings. Ifnecessary, the level
ofpressuresupportwas further titrated toachievepatientcom-
fort and a respiratory rate less than 30/min.
Noninvasive VentilationWeaning Protocol
When a treating clinician judged that a patient was ready to
wean, thepatientunderwentextubationand immediatelywas
providedwithnoninvasiveventilationvia facemask.Thenon-
invasiveventilatorwasconfiguredtodeliveranequivalent level
of inspiratory positive airway pressure to the level of pres-
sure support that was being provided by the invasive ventila-
tor and expiratory positive airway pressure equivalent to the
level of positive end-expiratory pressure. The level of inspi-
ratorypositiveairwaypressurewas then titrated toachievepa-
tient comfort and a respiratory rate less than 30/min. Every 2
hours, the patient was assessed for signs of distress or fa-
tigue. In the absence of distress or fatigue, the treating clini-
cian either removed the noninvasive ventilation mask to al-
lowaself-ventilationtrialor reducedthe levelofpositiveairway
Key Points
Question In adults in whomweaning from invasive mechanical
ventilation is difficult, does early extubation using a protocolized
noninvasive weaning regimen reduce the time to liberation from
ventilation compared with protocolized invasive weaning?
Findings In this randomized clinical trial that included 364 adults,
the median time to liberation from ventilation for patients
randomized to noninvasive weaning vs invasive weaning was 4.3
days vs 4.5 days, a difference that was not statistically significant.
Meaning Protocolizedweaningwith early extubation tononinvasive
ventilation comparedwith invasiveweaningdidnot significantly
shorten time to liberation fromall formsofmechanical ventilation.
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pressure by 2 cmH2O. Thenoninvasiveweaningprotocolwas
discontinued when the patient tolerated 12 hours of unsup-
ported spontaneous ventilation.
Invasive VentilationWeaning Protocol
Every2hours, a clinician assessedapatient for signsofdistress
or fatigue. In the absence of distress or fatigue, pressure sup-
portwas reduced by 2 cmH2O. This cyclewas repeated every 2
hoursas tolerated. If at anypoint thepatientdevelopedsignsof
distress or fatigue, then reversible causeswere sought and cor-
rective treatments initiated as appropriate. If this failed to re-
solve the situation, the level of pressure supportwas increased
by 2 cmH2O. Spontaneous breathing trials were repeated daily
toassessextubationreadiness.Thiscyclecontinueduntil either
the patient underwent extubation after a successful spontane-
ous breathing trial or a tracheostomywas performed.
In both groups, the fraction of inspired oxygen was ti-
tratedtomaintainarterialoxygensaturationsgreater than90%.
Bothactiveweaningprotocolswere implementedbetween8AM
and 10 PM. Unless a patient developed signs of fatigue or dis-
tress, ventilator settings remained unchanged overnight.
The protocol encouraged use of a ventilator bundle
(head-upposition; oral decontamination; sedationhold; pep-
tic ulcer prophylaxis) and recommendeddeferral of tracheos-
tomy until after 7 days of ventilation. Guidancewas provided
for the criteria for reintubation, but the decision to reintu-
bate was made by patients’ physicians. The decision to initi-
ate antibiotic therapy and other treatmentswas at the discre-
tion of patients’ physicians.
OutcomeMeasures
Theprimaryoutcomewas timefromrandomization tosuccess-
ful liberationfromventilation,definedasthetimepointatwhich
a patient was alive and free of ventilator (invasive or noninva-
sive)support formorethan48hours.Secondaryoutcomeswere
durationof invasiveventilationand total ventilatordays (inva-
sive and noninvasive); proportion of patients receiving antibi-
otics forpresumedrespiratory infection; totaldaysreceivingan-
tibiotics; rateof reintubation;mortalityat 30,90,and180days;
time to meeting ICU discharge criteria; and rate at which pa-
tients fulfilled predefined criteria indicating the need for rein-
tubation irrespective of whether they underwent reintuba-
tion. Thepredefined criteriawere cardiac or respiratory arrest,
respiratorypauseswith lossof consciousnessorgasping for air,
severe psychomotor agitation inadequately controlled by se-
dation, persistent inability to remove respiratory secretions,
heart rate of 50/min or lower or respiratory rate of 140/min
or higher with loss of alertness, hemodynamic instability
unresponsive to fluids and vasoactive drugs, requirement for
surgeryorother interventionalprocedure requiringdeepseda-
tion or anesthesia, proportion of patients receiving a tracheos-
tomy, and mortality at 30, 90, and 180 days after randomiza-
tion.Posthockeyprocessvariables (weaningpathway, sedation
use, length of ICU stay) are also reported. Outcomes were ex-
tracted from the ICU hospital clinical records and from ques-
tionnaires returnedbypatients.Becauseof thenatureof the in-
tervention and clinical record designs (which typically record
modeof ventilationalongside respiratoryvariables), itwasnot
possible for those assessing core ventilation outcomes to be
blinded to treatment allocation. Adverse events were defined
as development of skin or mucosal damage, vomiting, gastric
distension, non–respiratory tract infection, and cardiac dys-
rhythmias. Health-related quality of life was assessed by the
EQ-5D-5L(EuroQualityofLife5DimensionsQuestionnairewith
5 levels of severity for each of the 5 dimensions) and the Short
Form12at baseline (estimated retrospectively) and90and 180
days after randomization. All reported outcomes are postran-
domization results.
Statistical Analysis
The original sample size was 920 patients, but after a formal
review requested by the funder, the sample size was revised
to reflect a shorter than anticipated period of weaning. Ame-
dian duration of weaning of 2.9 days and a difference of 1 day
provided an associated hazard ratio of 1.53 and a minimum
sample size of 280 with 90% power at an α=.05 significance
level.Onedaywasdefinedby the investigators andpatient and
public representatives as theminimal clinically important dif-
ference. The sample size was inflated by 23% to account for
the rate of loss to follow-up seen up to the interim review of
the data. It also accounted for the shape parameter, p, which
was estimated by the data to be 0.918 and which allowed for
nonconstant hazards (as modeled by the Weibull distribu-
tion), resulting ina final samplesizeof364 (182patients ineach
group).Revisionof thesamplesizemeant that theprimaryout-
come would be analyzed using a Cox proportional hazards
model asopposed to thecompeting risks regressionmodel that
was prespecified in the protocol.
Theprimaryanalysismethodwas intention to treat.Analy-
sis of theprimaryoutcome, time fromrandomization to libera-
tion from ventilation, and other time to event outcomes used
a Cox proportional hazards regression model to estimate haz-
ard ratios and95%confidence intervals. In addition,weuseda
competing risks regression model to account for the compet-
ing risk of death. Prior to the competing risk regression analy-
sis, the cumulative incidence of liberation and deathwas plot-
ted as basic descriptive data to understand the overall pattern
over time.Mixed-effects logistic regressionmodels were used
to estimate the difference inmortality at 30, 90, and 180 days
between the 2 groups, for which odds ratios and 95% confi-
dence intervals are reported. Mixed-effects linear regression
modelswereused to estimatemean treatmentdifferences and
95% confidence intervals for continuous outcomes including
the health-related quality-of-lifemeasures (change frombase-
line).Mixed-effectsnegativebinomialmodelswereused toes-
timate incidence rate ratios and 95% confidence intervals for
overdispersed count data; eg, number of days on invasive ven-
tilation with zero inflation where several participants had no
dayson invasiveventilation.Thestudywasnotpowered tode-
tect treatment differences in secondary outcomes; hence, sec-
ondary analyses are considered exploratory.
We performed a per-protocol analysis and 2 predefined
subgroup analyses (presence or absence of COPD; postopera-
tive/nonoperative reason for ICU admission). It was not pos-
sible to perform the third planned subgroup analysis
(physician-led vs nurse-led weaning) because all sites used
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a multiprofessional approach involving both physicians and
nurses. Multiple imputation by chained equations was used
to imputemissingprimaryoutcomedata, andthe imputeddata
set was analyzed as a sensitivity analysis.
All of the analysesusedmixed-effectsmodels adjusted for
age, sex, center, post–spontaneousbreathing trial PaCO2, pres-
enceor absenceofCOPD, andpostoperative/nonoperative rea-
son for ICU admission, where center was included as a ran-
domeffect in themodels.Modelingassumptionswereassessed
for allmodels fitted.Theproportionalhazardsassumptionwas
assessedfor theCoxproportionalhazards regressionmodeland
the competing risks model using plots of the log(−log) sur-
vival function and the Schoenfeld residuals and by assessing
the influence of time-varying covariates. Linear, logistic, and
negative binomial regressionmodels were checked to ensure
that the assumptions of linearity and constant variance were
satisfiedusing residual plots. In addition to this, all the covar-
iates included in themodel were assumed to be independent
of the outcome.All statistical testswere 2-sidedusing aP<.05
significance threshold. Statistical analyses were performed
using Stata version 15.1 (StataCorp).
Results
Patients
Figure 1 shows the flow of patients through the trial. Recruit-
ment took place betweenMarch 2013 and October 2016, dur-
ing which 364 patients were recruited from across 41 hospi-
tals. Therewere 182 patients randomized to each group.Most
patients received their randomized intervention (invasive
group, 96.7% [176/182]; noninvasive group, 96.1% [175/182]).
Participant follow-up ended in April 2017. Overall base-
line and physiological characteristics of patients were well
matched (Table 1). For most patients, pneumonia (35.7%) or
postsurgery respiratory failure (21.4%)was themain reason for
mechanical ventilation.
Outcomes
The primary outcome, time from randomization to liberation
fromventilation, was amedian of 4.3 days (95%CI, 2.63-5.58
days) in thenoninvasive groupcomparedwith amedianof4.5
days (95% CI, 3.46-7.25 days) in the invasive group (adjusted
hazard ratio, 1.1; 95% CI, 0.89-1.40) (Figure 2). The compet-
ing risks regression analysis produced a similar result (ad-
justed hazard ratio, 1.1; 95% CI, 0.86-1.34) (Figure 3).
The noninvasive group required less invasive ventilation
(median, 1dayvs4days; incidence rate ratio,0.6;95%CI,0.47-
0.87) and required fewer total ventilator days (median, 3 days
vs 4 days; incidence rate ratio, 0.8; 95% CI, 0.62-1.0). Fewer
patients in thenoninvasive group received antibiotics for res-
piratory infection (60.4% vs 70.3%; unadjusted absolute dif-
ference,9.9%;95%CI,0.17%-19.61%).Thetotalnumberofdays
onwhich antibioticswere administered (respiratory andnon-
respiratory)wasnot significantly different,with ameanof 9.1
days (SD, 12.0 days) in the noninvasive group and 10.4 days
(SD, 13.2days) in the invasivegroup (meandifference, 1.3days;
95% CI, −1.31 to 3.88 days).
A higher proportion of patients underwent extubation in
the noninvasive group (181/182) compared with the invasive
group (143/182). Sixty-seven (37.0%) of 181 undergoing extu-
bation in thenoninvasivegroupunderwent reintubation com-
paredwith 41 (28.7%) of 143 in the invasive group (odds ratio,
1.54; 95%CI, 0.89-2.41). For the end point ofmeeting the cri-
teria for reintubation, therewere 63 of 181 patients (34.8%) in
thenoninvasive group comparedwith42of 143 (29.4%) in the
invasive group (odds ratio, 1.3; 95% CI, 0.78-2.12).
The rate of tracheostomy was 23.6% in the noninvasive
group and 30.2% in the invasive group (odds ratio, 0.7; 95%
CI, 0.44-1.15). Survival rates were not significantly different
at 30days (86.8% in thenoninvasive groupvs86.3% in the in-
vasive group; odds ratio, 1.1; 95%CI, 0.58-1.96) or at 180 days
(78% in thenoninvasive groupvs 73.1% in the invasive group;
odds ratio, 1.4; 95%CI, 0.85-2.27) (eTable 2 in Supplement 2).
Figure 1. Participant Flow Through a Randomized Clinical Trial
of Protocolized Early Extubation to NoninvasiveWeaning
vsProtocolized InvasiveWeaningAmongPatientsWithRespiratory Failure
1752 Patients underwent spontaneous
breathing trial
1388 Excluded
1320 Trial successful
68 Declined participation
364 Randomized
182 Included in primary analysisc
182 Randomized to receive invasive
ventilationa
176 Received intervention as
randomized
6 Did not receive intervention
as randomized
182 Randomized to receive
noninvasive ventilationb
175 Received intervention as
randomized
7 Did not receive intervention
as randomized
84 Completed 6-mo follow-up
24 Withdrawn from follow-up
(patient decision)
47 Died before 6 mo
27 Not available for 6-mo follow-up
93 Completed 6-mo follow-up
23 Withdrawn from follow-up
(patient decision)
38 Died before 6 mo
28 Not available for 6-mo follow-up
182 Included in primary analysisd
91 Completed 3-mo follow-up
20 Withdrawn from follow-up
(patient decision)
43 Died before 3 mo
28 Not available for 3-mo follow-up
95 Completed 3-mo follow-up
17 Withdrawn from follow-up
(patient decision)
38 Died before 3 mo
32 Not available for 3-mo follow-up
a Thirty-four patients in the invasive ventilation group died during their
inpatient stay. Three were withdrawn from the study during their inpatient
stay (1 refused participation after being retrospectively approached for
consent; 2 withdrew for personal reasons).
b Thirty-three patients in the noninvasive ventilation group died during their
inpatient stay. Three were withdrawn from the study during their inpatient
stay for personal reasons.
c One hundred sixty participants achieved liberation from ventilation.
Twenty-two participants were censored (19 died, 2 were withdrawn from
follow-up, and 1 was discharged without achieving liberation from ventilation
and lost to follow-up).
dOne hundred fifty-nine participants achieved liberation from ventilation.
Twenty-three participants were censored (22 died and 1 was discharged
without achieving liberation from ventilation and lost to follow-up).
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Therewereno significant differences in theproportionsof pa-
tients who experienced adverse events and serious adverse
events. Adverse events occurred in 45 patients (24.7%) in the
noninvasive group compared with 47 (25.8%) in the invasive
group. The distributions of adverse events and serious ad-
verse events were similar (Table 2).
Posthockeyprocessmeasures showed thatpatients in the
noninvasive group underwent extubation earlier than those
in the invasive group (median, 0.5 day [interquartile range
{IQR}, 0.5-1 day]) vs 3 days [IQR, 2-10 days]; adjusted hazard
ratio, 2.5; 95%CI, 2.01-3.15; P < .001). Among those requiring
reintubation, the noninvasive group underwent reintubation
at amedian of 2 days (IQR, 0.9-3.0 days) after randomization
comparedwith3.2days (IQR, 2.3-4.7days) in the invasiveven-
tilation group (P < .001). The noninvasive group received se-
dation for fewer days (mean, 4.1 [SD, 5.0] days vs 5.5 [SD, 5.1]
days; incidence rate ratio,0.7;95%CI,0.61-0.91) andspent less
time in critical care (mean, 10.8 [SD, 8.8] days vs 12.2 [SD, 8.4]
days; P = .02). The median time from randomization to tra-
cheostomy was 5.8 days (IQR, 3.71-8.46 days) in the invasive
group and 5.6 days (IQR, 3.43-8.46 days) in the noninvasive
group. There was no significant difference between the 2
groups (nonparametric P = .65).
Althoughhealth-relatedqualityof lifewas impaired(eTable
3 in Supplement 2), there was no significant difference be-
tween the 2 groups at 3 months or at 6 months.
The per-protocol analysis produced results similar to the
primary analysis (hazard ratio, 1.1; 95%CI, 0.90-1.44). The ex-
plored subgroups showed no significant difference in treat-
ment effect (eTable 4 in Supplement 2). The sensitivity analy-
sis using multiple imputation for the 45 participants with
missing (censored) primary outcome data found no differ-
ence between the 2 groups (hazard ratio, 1.1; 95% CI, 0.90-
1.36). A further sensitivity analysis found no significant dif-
ference in outcome between the 3 highest recruiting centers
(who recruited 161 patients [44%]) and the other participat-
ing centers. Therewere nomajor departures from themodel-
ing assumptions for all of the regression models fitted.
Table 1. Baseline Characteristics
Characteristics
Invasive Weaning
(n = 182)
Noninvasive
Weaning
(n = 182)
Age, mean (SD), y 61.8 (15.8) 64.3 (13.6)
Male, No. (%) 94 (51.6) 90 (49.5)
Evidence of delirium
(CAM-ICU positive), No. (%)a
17 (9.3) 23 (12.6)
Body mass index, mean (SD)b 27.7 (6.6) 28.2 (6.9)
Duration of ventilation prior
to randomization, median (IQR), d
4.7 (3.0-7.4) 5.3 (3.3-8.1)
Antibiotics for respiratory
infection, No. (%)
100 (55) 98 (54)
APACHE II score, mean (SD)c 18.8 (6.2) 18.9 (6.6)
Admission diagnosis, No. (%)
Pneumonia/respiratory infection 73 (40.1) 57 (31.3)
Postsurgery respiratory failure 39 (21.4) 39 (21.4)
Cardiac 18 (9.9) 27 (14.8)
Nonrespiratory infection 21 (11.5) 16 (8.8)
Neuromuscular 8 (4.4) 7 (3.9)
COPD/asthma exacerbation 7 (3.9) 7 (3.9)
Traumatic injuries 5 (2.8) 3 (1.6)
Gastrointestinal bleeding 3 (1.7) 7 (3.9)
Pancreatitis 1 (0.5) 4 (2.2)
Stroke 1 (0.5) 0
Otherd 6 (3.2) 15 (8.2)
Ventilation parameters prior
to spontaneous breathing trial
Exhaled minute volume,
median (IQR), L/min
10.5 (8.2-13.1) 10.2 (8.4-12.6)
Total respiratory rate,
median (IQR), /min
21 (17-27) 21 (16-27)
Positive end-expiratory pressure,
median (IQR), cm H2O
5 (5-8) 5 (5-8)
Pressure support, median (IQR),
cm H2O
11 (8-15) 11 (9-15)
P:F ratio, median (IQR), mm Hge 242.2 (200.6-315) 227.5 (196.9-280.7)
Spontaneous tidal volume,
median (IQR), mL/kg
8.2 (6.5-9.8) 7.9 (6.4-9.5)
Arterial blood gas measures prior
to spontaneous breathing trial
PaCO2, mean (SD), mm Hg 42.8 (10.2) (n=181) 42.6 (8.9) (n=180)
pH, mean (SD) 7.4 (0.06) (n=182) 7.4 (0.06) (n=181)
Hemoglobin, mean (SD), g/dL 9.7 (1.7) (n=182) 9.6 (1.6) (n=181)
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation;
COPD, chronic obstructive pulmonary disease; IQR, interquartile range.
a CAM-ICU is the Confusion Assessment Method for Screening for Evidence of
Delirium in Intensive Care (http://www.icudelirium.org).
b Calculated as weight in kilograms divided by height in meters squared.
c The APACHE II score ranges from0 to 71; higher scores correspond tomore
severe disease and higher risk of death. An APACHE II score of 10 to 19 is
associated with a 25% risk of in-hospital mortality.
dOther diagnoses included pulmonary hemorrhage (n = 1), bowel obstruction
(n = 2), acute renal failure (n = 2), metabolic disturbance (n = 2), liver failure
(n = 4), drug overdose (n = 2), respiratory failure of unknown cause (n = 5),
vasculitis (n = 1), and burns (n = 2).
e The P:F ratio is the partial pressure of oxygen in arterial blood divided by the
fraction of inspired oxygen.
Figure 2. Time to Liberation FromMechanical Ventilation
by Treatment Group
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Hashmarks indicate each censoring time. Median time to liberation from
ventilation was 4.5 days (95% CI, 3.46-7.25 days) in the invasive group and 4.3
days (95% CI, 2.63-5.58 days) in the noninvasive group.
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Discussion
In thismulticenter randomized trial, early extubation to non-
invasive ventilation compared with protocolized invasive
weaning with sequential pressure support reduction prior to
extubationdidnot reduce the time to liberation fromall forms
of ventilation. Consistent with the protocol design, patients
inthenoninvasiveventilationgroupunderwentextubationear-
lier and spent less time receiving invasive ventilation.Mortal-
ity rates, the requirement for reintubationor tracheostomy,and
adverse event rates were not significantly different.
Spontaneous breathing trials are used to identify patients
whoarereadyforextubation.16The59%to86%of invasiveven-
tilationpatients inwhomaspontaneousbreathing trial fails are
classified as difficult towean.1,4,17-19 These patients contribute
to a disproportionate amount of ICU resource utilization to
achievesuccessful liberation.11Noninvasiveventilationhasbeen
suggested tobeauseful tool to facilitateweaning,butmostpre-
viousstudies recruitedpredominantlypatientswithCOPD.20-24
In that patient group, noninvasiveweaning reducedmortality,
duration of invasive ventilation, reintubation, and ICU length
of stay.14 The patients enrolled in the present study better re-
flect contemporary ICU practice, as fewer patients with COPD
now undergo invasive ventilation.25,26
The rate of reintubation in this study was expected to be
higher than among patients with simple weaning needs, in
whom reintubation rates of 10% to 20% are reported.27 The
30%overall rate of reintubation is consistentwith findings in
previous studies that recruited patients with difficulty
weaning.21,22,24 Because more patients underwent extuba-
tion in the noninvasive group, more were at risk of reintuba-
tion. One of the major concerns about reintubation is the as-
sociationwith increasedmortality seen in someobservational
studies.28,29 The survival rates in the present study were not
significantly different in noninvasive and invasive weaning
groups,althoughthese findingsshouldbe interpretedwithcau-
tion because the studywas not powered to show a difference
in this outcome and was not designed to assess equivalence.
Thedesignof this studyaffordedseveraladvantages topre-
vious studies. First, a protocolized weaning regimen in both
groups allowed clear separation of the intervention from the
effect of protocolization.30 Best practice guidelines (ventila-
tion bundle, daily spontaneous breathing trials, tracheos-
tomy insertion) reduced heterogeneity between treatment
groups. Second, antibiotic use was selected as a surrogate for
ventilator-associated pneumonia to limit the risk of detec-
tion bias arising fromdifferent approaches to obtaining respi-
ratory samples for culture; this outcome is arguablymore rel-
evant than ventilator-associated pneumonia diagnosis as it
better reflects antibiotic stewardship and exposure.
Limitations
The study has several limitations. First, the nature of the in-
tervention prevented blinding of clinicians, patients, or out-
come assessors. Thismay have led to performance and/or de-
tection bias. Second, the noninvasive weaning protocol
mandated sequential reductions in respiratory support (either
adecrease in inspiratorypressure supportor abreak fromnon-
invasiveventilation) as toleratedover aminimumof a 12-hour
period. It is possible that this may have extended the period
Figure 3. Cumulative Incidence of Liberation FromVentilation or Death
by Treatment Group
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Table 2. Adverse Events
Adverse Events
No. (%) of Participants
Unadjusted Absolute
Difference, % (95% CI)
Invasive Weaning
(n=182)
Noninvasive Weaning
(n=182)
Antibiotics for presumed
respiratory infection
128 (70.3) 110 (60.4) 9.9 (0.2 to 19.6)
Reintubation 41 (28.7)(n=143) 67 (37.0)(n=181) 8.3 (−1.9 to 18.6)
Tracheostomy 55 (30.2) 43 (23.6) 6.6 (−2.5 to 15.7)
Death before intensive care unit
discharge
25 (13.7) 22 (12.1) 1.6 (−5.2 to 8.5)
Dysrhythmias 22 (12.1) 14 (7.7) 4.4 (−1.7 to 10.5)
Nasal/skin/mouth sores or
irritation
14 (7.7) 19 (10.4) 2.7 (−3.2 to 8.6)
Nonrespiratory infection 12 (6.6) 11 (6.0) 0.5 (−4.5 to 5.6)
Vomiting 8 (4.4) 14 (7.7) 3.3 (−1.6 to 8.2)
Gastric distension 6 (3.3) 7 (3.9) 0.5 (−3.3 to 4.4)
Barotrauma (eg, pneumothorax) 3 (1.7) 3 (1.7) 0 (−2.6 to 2.6)
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of ventilatory support for some patients. Third, in the inva-
sive ventilation group, theprotocol requiredonce-daily spon-
taneous breathing trials. It is possible that more frequent
spontaneous breathing trials may have led to earlier recogni-
tion of readiness for extubation in some patients. Fourth,
the patients enrolledwere a heterogeneous group of patients
withdifferingrelativecontributionsof respiratory,cardiac,neu-
romuscular, metabolic, pharmacological, and neuropsycho-
logical impairment.Whether amorephysiologically based as-
sessmentprocess could identify a groupmore likely to benefit
fromnoninvasive ventilation remains to be determined in fu-
ture studies. Fifth, 44% of the patients were recruited from
3 centers,which could limit generalizability. It is possible that
performance andoutcomesmayhave improvedas centers be-
came more experienced in the use of the noninvasive wean-
ing intervention.
Conclusions
Among patients requiring mechanical ventilation in whom a
spontaneous breathing trial had failed, early extubation to
noninvasiveventilationdidnot shorten time to liberation from
any ventilation.
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